• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Section Contents Menu

Drug Safety and Availability

Drug Safety Communications - Volume 1, Number 3, Spring 2008

Drug Safety Communications posted by FDA from January 1, 2008 to April 30, 2008 (advisories are available at http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm)

 

Date Product(s) Safety Issue and Web Address
April 25, 2008 Heparin sodium injection Update on heparin and heparin-containing medical products and new information about a contaminant, oversulfated chondroitin sulfate, in the heparin.
April 10, 2008 Mycophenolate mofetil (CellCept) and Mycophenolate acid (Myfortic) 1 Ongoing safety review to evaluate the potential risk of progressive multifocal leukoencephalopathy (PML).
March 27, 2008 Becaplermin (Regranex) 1 Ongoing safety review of possible increased risk of cancer in patients with diabetes mellitus based upon a health insurance database study.
March 27, 2008 Ziagen (Abacavir) and Videx (Didanosine) 1 Ongoing safety review of potential risk of myocardial infarction based upon a large observational study to evaluate the short and long-term adverse effects of treatment with anti-HIV drugs.
March 27, 2008 Montelukast (Singulair) 1 Ongoing safety review of reports of behavior/mood changes, suicidality (suicidal thinking and behavior) and suicide.
March 21, 2008 Darunavir etalolate (Prezista) Highlighting new labeled warnings about potential risk of hepatotoxicity.
March 18, 2008 Tiotropium bromide inhalation powder (Spiriva HandiHaler) Ongoing safety review to evaluate the potential risk of stroke based upon the pooled analysis from 29 placebo controlled studies.
March 11, 2008 Long-Acting Hydrocodone-containing cough product (Tussionex Pennkinetic Extended-Release Suspension) Reports of serious adverse events, including death due to respiratory depression, associated with overdose and misuse of the product in all age groups, especially in children under 6 years of age for whom the product is not recommended.
March 5, 2008 Long-Acting Beta Agonists (LABAs) [salmeterol xinafoate (Serevent Diskus), fluticasone propionate; salmeterol xinafoate (Advair Diskus, Advair HFA), formoterol fumarate (Foradil Aerolizer, Perforomist) butenoside; formoterol fumarate dehydrate (Symbicort), aformotrol tartrate (Brovana)] Update highlighting an ongoing benefit/risk assessment of LABAs in children with asthma.
February 29, 2008 Tiotropium bromide inhalation powder (Spiriva HandiHaler) and formoterol fumarate inhalation powder (Foradil Aerolizer) Highlighting the correct use of Spiriva and Foradil capsules after receiving reports of patients swallowing the capsules rather than placing the capsules in the inhalation devices.
February 11, 2008 (updated February 28, 2008 and April 25, 2008) Heparin sodium injection Reports of serious allergic reactions and severe hypotension following the administration of Baxter's multi-dose vials of heparin sodium injection and temporary suspension of the marketing of the product.
February 8, 2008 Botulinum toxin Type A (Botox and Botox Cosmetic ) and Botulinum toxin Type B (Myobloc) 1 Ongoing safety review of reports of systemic adverse reactions including respiratory compromise and death, occurring mostly in children treated for cerebral palsy-associated limb spasticity.
February 1, 2008 Varenicline (Chantix) Update highlighting new labeled warnings and precautions about the potential risk of neuropsychiatric symptoms.
January 31, 2008 Antiepileptic drugs [carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol XR), felbamate (Felbatol) , gabapentin (Neurontin), lamotrigine (Lamictal), levetiracetam (Keppra), oxcarbazepine (Trileptal), pregabalin (Lyrica), tiagabine (Gabitril), topiramate (Topamax), valproate (Depakote, (Depakote ER, Depakene, Depacon), zonisamide (Zonegran)] Increased risk of suicidal behavior or ideation in patients who received antiepileptic drugs compared to the placebo group in randomized clinical studies of eleven drugs.
January 25, 2008 Ezetimibe/Simvastatin (Vytorin), Ezetimibe (Zetia) 1 Ongoing data review evaluating the overall cardiovascular benefits of ezetimibe with simvastatin combination therapy. Preliminary findings suggest no benefit of combined ezetimibe and simvastatin over simvastation alone.
January 17, 2008 Nonprescription cough and cold drug products Update of safety review findings that over-the-counter (OTC) cough and cold medicines should not be used to treat infants and children less than 2 years of age because of serious and potentially life-threatening adverse events.
January 16, 2008 Edetate disodium (Endrate and generics) Reports of death in children and adults who were mistakenly given Edetate Disodium instead of Edetate Calcium Disodium (Calcium Disodium Versenate) during intravenous chelation therapy.
January 7, 2008 Bisphosphonates [alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and zoledronic acid (Reclast, Zometa)] Reports of severe and incapacitating musculoskeletal pain in patients taking bisphosphonates.
January 3, 2008 Erythropoiesis Stimulating Agents (ESAs) [darbepoetin alfa (Aranesp), epoetin alfa (Epogen), epoetin alfa (Procrit)] 1 Increased risk of death and tumor progression in patients with cancer who received ESAs for treatment of chemotherapy-induced anemia.

Footnotes:

  1. Early Communication about Ongoing Safety Review.

 

Page created: June 12, 2008